Funds › ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC
13F for Q2 2026, filed Aug 14, 2026. 262 positions worth $2.2B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$2.2B
+$486.5M (28.6%) vs Q1 2026
Positions
262
291 in Q1 2026
Top 10 share
40.8%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of ADAR1 Capital Management, LLC in the latest 13F quarter?
Using 13F.ai, how has ADAR1 Capital Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of ADAR1 Capital Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | ABVX Abivax SA · ADR | 1.80M | $240.5M | 11.0% | +29.5% | 13F ↗ |
| 2 | PTGX Protagonist Therapeutics, Inc. | 960,863 | $117.8M | 5.4% | -3.3% | 13F ↗ |
| 3 | ROIV Roivant Sciences Ltd. | 3.16M | $111.7M | 5.1% | -3.9% | 13F ↗ |
| 4 | SPY State Street SPDR S&P 500 ETF Trust · Trust units | 129,087 | $96.4M | 4.4% | +70.0% | 13F ↗ |
| 5 | IMVT Immunovant, Inc. | 2.33M | $89.8M | 4.1% | -13.0% | 13F ↗ |
| 6 | ZLAB Zai Lab Limited · ADR | 3.37M | $64.0M | 2.9% | +136% | 13F ↗ |
| 7 | AGIO Agios Pharmaceuticals, Inc. | 1.29M | $47.8M | 2.2% | +816% | 13F ↗ |
| 8 | Crinetics Pharmaceuticals In | 1.22M | $45.7M | 2.1% | +7.3% | 13F ↗ |
| 9 | Ea Series Trust Alpha Arch 1-3 | 337,125 | $39.5M | 1.8% | Unchanged | 13F ↗ |
| 10 | CYTK Cytokinetics, Incorporated | 457,907 | $39.0M | 1.8% | -27.6% | 13F ↗ |
| 11 | SEPN Septerna, Inc. | 940,747 | $31.5M | 1.4% | -13.7% | 13F ↗ |
| 12 | AVR Anteris Technologies Global Corp. | 3.15M | $31.0M | 1.4% | -17.0% | 13F ↗ |
| 13 | EDIT Editas Medicine, Inc. | 8.89M | $28.8M | 1.3% | New | 13F ↗ |
| 14 | DNLI Denali Therapeutics Inc. | 1.03M | $26.5M | 1.2% | -45.0% | 13F ↗ |
| 15 | SYRE Spyre Therapeutics, Inc. | 283,982 | $25.2M | 1.2% | -16.1% | 13F ↗ |
| 16 | VIR Vir Biotechnology, Inc. | 2.46M | $25.0M | 1.1% | -10.5% | 13F ↗ |
| 17 | PRAX Praxis Precision Medicines, Inc. | 74,253 | $24.9M | 1.1% | +4850% | 13F ↗ |
| 18 | INSM Insmed Incorporated · Com Par $.01 | 228,520 | $24.4M | 1.1% | +546% | 13F ↗ |
| 19 | CLDX Celldex Therapeutics, Inc. | 619,542 | $23.1M | 1.1% | +44.8% | 13F ↗ |
| 20 | VKTX Viking Therapeutics, Inc. | 574,038 | $22.4M | 1.0% | +152% | 13F ↗ |
| 21 | TSHA Taysha Gene Therapies, Inc. | 3.04M | $20.7M | 0.9% | +2.0% | 13F ↗ |
| 22 | MNPR Monopar Therapeutics Inc. | 217,595 | $20.1M | 0.9% | -17.7% | 13F ↗ |
| 23 | OVID Ovid Therapeutics Inc. | 7.42M | $20.0M | 0.9% | +63.2% | 13F ↗ |
| 24 | ELVN Enliven Therapeutics, Inc. | 387,718 | $19.7M | 0.9% | +17.7% | 13F ↗ |
| 25 | ENTA Enanta Pharmaceuticals, Inc. | 1.34M | $19.6M | 0.9% | +2518% | 13F ↗ |
| 26 | NKTR Nektar Therapeutics | 244,184 | $17.0M | 0.8% | +51.4% | 13F ↗ |
| 27 | INSP Inspire Medical Systems, Inc. | 374,617 | $16.7M | 0.8% | -7.5% | 13F ↗ |
| 28 | RVMD Revolution Medicines, Inc. | 87,509 | $16.4M | 0.7% | -34.6% | 13F ↗ |
| 29 | ESTA Establishment Labs Holdings Inc. | 185,619 | $15.9M | 0.7% | -13.0% | 13F ↗ |
| 30 | PRTA Prothena Corporation plc | 1.55M | $15.2M | 0.7% | -1.7% | 13F ↗ |
| 31 | RYTM Rhythm Pharmaceuticals, Inc. | 136,158 | $15.1M | 0.7% | -35.6% | 13F ↗ |
| 32 | IKT Inhibikase Therapeutics, Inc. | 7.39M | $15.0M | 0.7% | +11.8% | 13F ↗ |
| 33 | QURE uniQure N.V. | 324,672 | $15.0M | 0.7% | +326% | 13F ↗ |
| 34 | RLYB Rallybio Corporation | 926,352 | $14.8M | 0.7% | +4411% | 13F ↗ |
| 35 | REGN Regeneron Pharmaceuticals, Inc. | 22,208 | $13.8M | 0.6% | +82.7% | 13F ↗ |
| 36 | IVA Inventiva S.A. · ADR | 3.61M | $13.6M | 0.6% | +65.9% | 13F ↗ |
| 37 | STRO Sutro Biopharma, Inc. | 404,014 | $13.4M | 0.6% | -23.0% | 13F ↗ |
| 38 | IONS Ionis Pharmaceuticals, Inc. | 166,286 | $13.2M | 0.6% | +3.7% | 13F ↗ |
| 39 | BBIO BridgeBio Pharma, Inc. | 176,689 | $13.2M | 0.6% | +87.4% | 13F ↗ |
| 40 | SRPT Sarepta Therapeutics, Inc. | 730,649 | $13.1M | 0.6% | +179% | 13F ↗ |
| 41 | CTMX CytomX Therapeutics, Inc. | 3.37M | $12.6M | 0.6% | -1.3% | 13F ↗ |
| 42 | VOR Vor Biopharma Inc. | 680,626 | $12.5M | 0.6% | New | 13F ↗ |
| 43 | Spdr Series Trust St Str Blo 1 Etf | 135,585 | $12.4M | 0.6% | Unchanged | 13F ↗ |
| 44 | EQ Equillium, Inc. | 3.76M | $12.0M | 0.6% | +0.9% | 13F ↗ |
| 45 | ANL Adlai Nortye Group Ltd. · ADR | 1.02M | $11.7M | 0.5% | +763% | 13F ↗ |
| 46 | CLYM Climb Bio, Inc. | 822,649 | $10.7M | 0.5% | +37.6% | 13F ↗ |
| 47 | HLXC Helix Acquisition Corp. III | 1.00M | $10.6M | 0.5% | Unchanged | 13F ↗ |
| 48 | ZURA Zura Bio Limited | 1.76M | $10.4M | 0.5% | +179% | 13F ↗ |
| 49 | OKUR OnKure Therapeutics, Inc. | 2.24M | $10.2M | 0.5% | -8.1% | 13F ↗ |
| 50 | MAZE Maze Therapeutics, Inc. | 339,276 | $10.1M | 0.5% | +577% | 13F ↗ |
Showing the top 50 of 262 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
43 new, 96 added to, 65 trimmed, 72 exited, 58 unchanged. By estimated dollars.
New positions (43)
| EDIT Editas Medicine, Inc. | 8.89M | New | $28.8M |
| VOR Vor Biopharma Inc. | 680,626 | New | $12.5M |
| FTH Faeth Therapeutics, Inc. | 361,010 | New | $9.0M |
| ASND Ascendis Pharma A/S | 28,604 | New | $7.6M |
| AMAN Amanat Acquisition Corp | 750,000 | New | $7.6M |
| RACC Research Alliance Corporation III | 650,000 | New | $7.0M |
| RLAY Relay Therapeutics, Inc. | 358,333 | New | $6.7M |
| Disciplined Growth Acquis Co Units | 500,000 | New | $5.0M |
| BOLD Boundless Bio, Inc. | 1.97M | New | $4.9M |
| AVLN Avalyn Pharma Inc. | 146,447 | New | $4.8M |
Added to (96)
| ABVX Abivax SA · ADR | 1.80M | +29.5% | $54.7M |
| AGIO Agios Pharmaceuticals, Inc. | 1.29M | +816% | $42.6M |
| SPY State Street SPDR S&P 500 ETF Trust · Trust units | 129,087 | +70.0% | $39.7M |
| ZLAB Zai Lab Limited · ADR | 3.37M | +136% | $36.9M |
| PRAX Praxis Precision Medicines, Inc. | 74,253 | +4850% | $24.4M |
| INSM Insmed Incorporated · Com Par $.01 | 228,520 | +546% | $20.6M |
| ENTA Enanta Pharmaceuticals, Inc. | 1.34M | +2518% | $18.9M |
| RLYB Rallybio Corporation | 926,352 | +4411% | $14.5M |
| VKTX Viking Therapeutics, Inc. | 574,038 | +152% | $13.5M |
| QURE uniQure N.V. | 324,672 | +326% | $11.4M |
Trimmed (65)
| DNLI Denali Therapeutics Inc. | 1.03M | -45.0% | -$21.7M |
| CYTK Cytokinetics, Incorporated | 457,907 | -27.6% | -$14.9M |
| IMVT Immunovant, Inc. | 2.33M | -13.0% | -$13.4M |
| MPLT MapLight Therapeutics, Inc. | 26,497 | -92.9% | -$12.5M |
| SNY Sanofi | 57,100 | -82.0% | -$11.1M |
| REPL Replimune Group, Inc. | 655,784 | -58.6% | -$10.3M |
| AMLX Amylyx Pharmaceuticals, Inc. | 494,378 | -50.6% | -$9.1M |
| ABUS Arbutus Biopharma Corporation | 1.27M | -59.5% | -$9.0M |
| RVMD Revolution Medicines, Inc. | 87,509 | -34.6% | -$8.7M |
| MLTX MoonLake Immunotherapeutics | 27,000 | -94.1% | -$8.4M |
Exited (72)
| Terns Pharmaceuticals Inc | 914,699 | Exited | -$48.2M |
| BEAM Beam Therapeutics Inc. | 1.45M | Exited | -$34.5M |
| SRRK Scholar Rock Holding Corporation | 407,273 | Exited | -$20.0M |
| VRTX Vertex Pharmaceuticals Incorporated | 15,075 | Exited | -$6.7M |
| VRDN Viridian Therapeutics, Inc. | 304,422 | Exited | -$6.0M |
| Ascendis Pharma A/S ADR | 25,014 | Exited | -$5.7M |
| LLY Eli Lilly and Company | 5,060 | Exited | -$4.7M |
| DNTH Dianthus Therapeutics, Inc. | 55,000 | Exited | -$4.6M |
| BLTE Belite Bio, Inc | 26,880 | Exited | -$4.3M |
| Arcellx Inc | 32,084 | Exited | -$3.7M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 13F-HR | 277 | $2.2B | Current | SEC ↗ |
| Q1 2026 | May 18, 2026 | 13F-HR | 310 | $1.7B | Current | SEC ↗ |
| Q4 2025 | Feb 18, 2026 | 13F-HR/A (restatement) | 270 | $1.4B | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 270 | $1.4B | Replaced | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 217 | $1.1B | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 210 | $652.1M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 202 | $538.7M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer